You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)預期年度純利大增超4倍至約140億元以上
格隆匯 03-15 17:28

格隆匯3月15日丨中國生物製藥(01177.HK)公吿,公司預期截至2021年12月31日止年度的歸屬於母公司持有者應占盈利較去年同比增長超過4倍至約人民幣140億元以上(去年歸屬於母公司持有者應占盈利為人民幣27.71億元)。

歸屬於母公司持有者應占盈利同比大幅增長主要受惠於:(1)集團主營業務表現令人滿意,年內新產品、高毛利率產品銷售佔比上升,使集團整體收入及毛利率同比明顯提升;及(2)聯營公司財務表現強勁,集團應占聯營公司及合營公司盈虧同比大幅增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account